Sort   by:  
 Page size 
UnknownSARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.
Not available
S-EPMC7273245 | biostudies-literature
UnknownSARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
Not available
S-EPMC7499171 | biostudies-literature
UnknownPrevious exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Not available
S-EPMC10619466 | biostudies-literature
UnknownUse of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.
Not available
S-EPMC8096267 | biostudies-literature
UnknownLimited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Not available
S-EPMC9279157 | biostudies-literature
ProteomicsMolecular Basis of Oligopeptide Recognition and Transport in the Pneumococcal Ami permease system
dataset to create a peptide candidate list of E. coli peptides bound to either AliB or AmiA from Streptococcus pneumoniae.
ORGANISM(S): Escherichia Coli Bl21 (ncbitaxon:511693) 
2023-08-23 | MSV000092727 | MassIVE
UnknownSeverity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013-19: a surveillance-based cohort study.
Not available
S-EPMC9876808 | biostudies-literature
UnknownCorticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study.
Not available
S-EPMC7095489 | biostudies-literature
UnknownRemdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
Not available
S-EPMC9060606 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327 | biostudies-literature
Sort   by:  
 Page size